THE MATERIALS YOU ARE SEEKING TO ACCESS (I) DO NOT CONSTITUTE OR FORM A PART OF ANY OFFER OR SOLICITATION TO PURCHASE SECURITIES AND (II) ARE NOT DIRECTED AT AND MAY NOT BE VIEWED BY OR DISTRIBUTED TO PERSONS
BY CLICKING THE BUTTON BELOW LABELLED “I AGREE”, YOU ARE CERTIFYING THAT (A) YOU ARE NOT IN THE UNITED STATES OR A U.S. PERSON; (B) IF YOU ARE IN THE EUROPEAN ECONOMIC AREA OR IN THE UK, YOU ARE A “QUALIFIED INVESTOR”; (C) IF YOU ARE IN THE UNITED KINGDOM, YOU ARE A “RELEVANT PERSON”; (D) YOU ARE NOT ACCESSING THIS WEBSITE FROM AUSTRALIA, CANADA OR JAPAN; AND YOU ARE NOT LOCATED IN A JURISDICTION WHERE IT IS UNLAWFUL TO DO SO; AND (E) IF YOU ARE ACTING AS A FINANCIAL INTERMEDIARY, THE SECURITIES ACQUIRED BY YOU AS A FINANCIAL INTERMEDIARY IN THE OFFER HAVE NOT BEEN ACQUIRED ON A NON-DISCRETIONARY BASIS ON BEHALF OF, NOR HAVE THEY BEEN ACQUIRED WITH A VIEW TO THEIR OFFER OR RESALE TO, ANY PERSON IN CIRCUMSTANCES WHICH MAY GIVE RISE TO AN OFFER OF ANY SECURITIES TO THE PUBLIC OTHER THAN THEIR OFFER OR RESALE IN ANY MEMBER STATE OF THE EEA OR IN THE UK WHICH HAS IMPLEMENTED THE PROSPECTUS REGULATION TO QUALIFIED INVESTORS (AS DEFINED IN THE PROSPECTUS REGULATION).
IF YOU CANNOT SO CERTIFY, YOU MUST CLICK THE BUTTON LABELLED “I DISAGREE” OR OTHERWISE EXIT THIS WEBSITE.
BY ACCESSING THE MATERIALS ON THIS WEBSITE, YOU SHALL BE DEEMED TO HAVE MADE THE ABOVE REPRESENTATIONS AND CONSENTED TO DELIVERY BY ELECTRONIC TRANSMISSION.
Investor Relations
Detailed information related to Lundbeck’s financial performance. Contact Palle Olesen, VP Investor Relations. + 45 3083 2426
About Us
A global pharmaceutical company specialized in brain diseases.
Press
Lundbeck seeks an open dialogue with the press. For general press enquiries, please call + 45 3643 4000